BMA hits back at claims it refused to allow doctors to work in critical areas during strike
Resident doctors – previously known as junior doctors – began a five day strike across England on Friday as part of an escalating row between NHS bosses and the BMA over pay.
The strike ended at 7am this morning (Wednesday).
During a strike, NHS trusts can apply for measures, often called "derogations", which would allow doctors to return to work providing critical services when it is feared patient safety is at risk.
In an update to staff on Tuesday morning, Sir James Mackey, chief executive of the NHS, said 18 requests for patient safety mitigations (derogations) had been turned down.
Sir Jim claimed that in nine of the 18 cases, the BMA said it would allow doctors to return to work, but only if they were paid "extortionate" rates.
"Unfortunately, despite all requests being made and verified by senior medics, 18 have been rejected by the BMA, with half of those rejections saying the BMA would support only if extortionate pay rates were offered to striking doctors," Sir James said.
But a spokesperson for the BMA told Sky News the claims by Sir James were "untrue and unfounded".
"When a derogation is agreed between the BMA and NHS England and which requires a resident doctor to return to work, they do not receive any kind of enhanced payment because those resident doctors are going back to their ward or department to do their usual work," they said.
"Sir James is clearly quite confused about the derogation process if he is suggesting anything different."
'Wholly wrong and untrue'
The BMA said before any derogation is granted, a trust is expected to demonstrate it has "done everything possible to incentivise non-striking doctors to cover the vacant shifts".
Read more:
"This can include paying enhanced rates of pay and this is a usual practice when asking doctors to take on extra-contractual work, over and above their normal hours and is not exclusive to covering gaps that trusts have failed to adequately plan for during industrial action."
They said the claim that the BMA requires increased payments to striking doctors is "wholly wrong and Sir James Mackey should withdraw these comments and apologise for the misleading impression they are creating".
Fewer patients were affected by the five-day walkout compared to previous strikes, NHS officials said this morning, with fewer doctors taking to picket lines.
The number of appointments, procedures and operations that were postponed are expected to be published later this week.
But as this week's strike comes to an end, the union is not ruling out further strikes.
Health Secretary Wes Streeting has said future talks could lead to improvements in the working lives of resident doctors but he has repeatedly said there is no more money for pay.
But BMA leaders have insisted there must be some discussion around pay.
Last July, resident doctors were awarded a raise of 22% over two years, the highest public sector award in recent years.
But the BMA has argued that pay has declined significantly since 2008, and are calling for a rise of 29.2% to reverse "pay erosion".

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
PL BioScience Announces Major Site Expansion
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production Site provides the world's largest HPL output with 20,000L annual capacity and a dual-source GMP strategy for secure, resilient supply from Aachen AACHEN, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements. Located in Aachen, the new headquarters offer more than 1,200 m² of usable space, with dedicated production and storage areas alongside office space to accommodate the company's continued growth. The expansion will enable the company to produce up to 20,000L of GMP-grade HPL per year, positioning it as the largest provider of HPL products worldwide. It will also provide more highly skilled jobs in the region. This large in-house production capacity makes PL BioScience the first company in the HPL industry with a two-source, GMP-grade strategy when combined with the current production hub. Securing a reliable supply of HPL while strengthening the resilience of its manufacturing operations positions PL BioScience as a leading source of this essential ingredient for cell culture, including the production of life-saving cell therapies. 'This is a major step forward for PL BioScience,' said Dr. Hatim Hemeda, CEO of the German biotech. 'With the new headquarters, we are accelerating our growth and strengthening our future production capabilities in response to growing global demand for HPL products. In addition, this expansion marks a significant step toward accelerating product innovation, including the further development of our new artificial HPL, the world's first scalable, fully lab-made HPL solution.' The facility will serve as a hub for research and product innovation, supporting the development of next-generation HPL-based media, such as artificial HPL. This recent innovation by PL BioScience is HPL produced from artificial platelets via a proprietary process, which can be developed into a nearly unlimited supply of a superior cell culture supplement. Other advanced products are in development, including specialized products tailored to the needs of different cell manufacturing applications, such as CAR-T cell manufacturing. The opening of the new headquarters is a key milestone in PL BioScience's long-term strategy to deliver high-quality cell culture supplements to customers and meet increasing global demand for its products. The company will move to the new facility, integrating operations under a shared organizational vision, in September 2025. About Human Platelet Lysate: HPL is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. Natural HPL is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable yet limited alternative to animal-derived cell culture supplements. A next-generation, fully artificial alternative made from lab-grown platelets has been developed by PL BioScience to secure the future supply. In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices. ELAREM™, PL BioScience's line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients. About PL BioScience: PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL allowing for a fully lab-made, scalable supply of HPL in the future. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: Contact:Dr. Hatim Hemeda, CEOPL BioScience GmbH+49(0)24195719-100info@ Media contact:MC Services AGRaimund Gabriel, Dr. Regina Lutz+49 (0)89 210 228 0 U.S.: Catherine Featherston+1-203-444-4393E-Mail: plbioscience@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Crow returns to visit vet who treated it for a fractured wing
A vet who helped a crow fly again after it suffered a fractured wing has said he feels he 'truly made a difference' because the bird keeps returning to visit him. The crow was taken to Portsmouth Vets for Pets practice owner Dr Justyn Loveridge after it was found by a member of the public. An X-ray showed it had fractured a bone and Dr Loveridge assessed that the wing could be repaired and the bird rehabilitated with a couple of weeks of care. So he checked with his fiancee that she would not object to him bringing the crow home to care for it. He said: 'I called Sally, my fiancee, straight away to ask if I could bring the crow home, but I already knew she'd say yes; we both love animals.' They decided to name it Morrigan, after the goddess of war in Irish mythology, who is known for her strong character and presence and is often depicted as a crow. Dr Loveridge said: 'Crows are omnivores, so I bought a mix of everything: insect mix, peanuts, chopped tomatoes, and even blueberries, which were a firm favourite with Morrigan. 'Obviously, with the lack of exercise, I was concerned about potential weight issues, so we kept portion sizes minimal to avoid overfeeding.' He said that after two weeks, Morrigan had recovered, and they released it from its crate in the garden and the bird flew away. But Dr Loveridge said he was surprised when Morrigan kept returning to visit. He said: 'There's a lot of evidence to suggest that crows are just as clever as primates. Knowing that an intelligent animal keeps coming back to visit makes me feel like I've truly made a difference.' Dr Loveridge said he was inspired to become a vet by a grandmother who was also an animal lover and rehomed stray cats, and he went on to open his Vets for Pets practice in 2012.